News
December 16, 2014

Legal Considerations For Pharmaceutical Brand Protection Programs

Bloomberg BNA's Pharmaceutical Law & Industry Report

By Ryan D. Guilds E. Alex Beroukhim
Find more content tagged:

People

Ryan D. Guilds
Ryan D. Guilds
Counsel
Washington, DC
+1 202.942.6188
Email
VCard
E. Alex Beroukhim
E. Alex Beroukhim
Partner
Los Angeles
+1 213.243.4059
Email
VCard

Related Content

September 10, 2021
President Biden Issues Executive Order Requiring COVID-19 Safeguards for US Government Prime Contractors and Subcontractors
Advisory
August 20, 2021
New Developments in China’s Drug Change Management Regulations
Advisory
August 12, 2021
FDA Seeks Comments on Transition of Certain Drugs to Device Status Following Genus DC Circuit Decision
Advisory
Subscribe
Subscribe Link

Email Disclaimer

Reject Accept